← FDA DRUG APPROVALS
FDA ANDA · ANDA090309
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE
Sponsor: MYLAN PHARMA
APPLICATION
ANDA090309
TYPE
ANDA
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
None (Tentative Approval)
Products
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINENone (Tentative Approval)
ABACAVIR SULFATE EQ 300MG BASE, LAMIVUDINE 150MG, ZIDOVUDINE 300MG · TABLET · ORAL
Approval history
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.